Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma-Reference-Cited by-同舟云学术

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

Published:2015-01 Issue:1 Volume:27 Page:85-96
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Girotti Maria Romina,Lopes Filipa,Preece Natasha,Niculescu-Duvaz Dan,Zambon Alfonso,Davies Lawrence,Whittaker Steven,Saturno Grazia,Viros Amaya,Pedersen Malin,Suijkerbuijk Bart M.J.M.,Menard Delphine,McLeary Robert,Johnson Louise,Fish Laura,Ejiama Sarah,Sanchez-Laorden Berta,Hohloch Juliane,Carragher Neil,Macleod Kenneth,Ashton Garry,Marusiak Anna A.,Fusi Alberto,Brognard John,Frame Margaret,Lorigan Paul,Marais Richard,Springer Caroline

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference39 articles.

1. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors;Ackerman;Cancer,2014

2. The selectivity of protein kinase inhibitors: a further update;Bain;Biochem. J.,2007

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011

4. Oncogenic Braf induces melanocyte senescence and melanoma in mice;Dhomen;Cancer Cell,2009

5. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma;Fedorenko;Biochem. Pharmacol.,2011

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers;Advanced Science;2024-09-10

2. Gentamicin Induces Selective Toxicity in Metabolically Altered Vemurafenib-Resistant A375 Cells;Hacettepe Journal of Biology and Chemistry;2024-07-01

3. Novel Quinoline‐Based RAF Inhibitors: A Comprehensive Review on Synthesis, SAR and Molecular Docking Studies;ChemistrySelect;2024-06-18

4. Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node;Molecular Oncology;2024-02-16

5. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26